NASDAQ:ONCT

Oncternal Therapeutics Competitors

$8.26
-1.08 (-11.56 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.81
Now: $8.26
$9.08
50-Day Range
$5.19
MA: $7.50
$9.39
52-Week Range
$1.49
Now: $8.26
$10.56
Volume2.80 million shs
Average Volume1.70 million shs
Market Capitalization$407.75 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66

Competitors

Oncternal Therapeutics (NASDAQ:ONCT) Vs. HRMY, TVTX, ZNTL, GBIO, KRON, and QURE

Should you be buying ONCT stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Oncternal Therapeutics, including Harmony Biosciences (HRMY), Travere Therapeutics (TVTX), Zentalis Pharmaceuticals (ZNTL), Generation Bio (GBIO), Kronos Bio (KRON), and uniQure (QURE).

Oncternal Therapeutics (NASDAQ:ONCT) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent ratings and target prices for Oncternal Therapeutics and Harmony Biosciences, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncternal Therapeutics00503.00
Harmony Biosciences00303.00

Oncternal Therapeutics presently has a consensus price target of $15.20, indicating a potential upside of 84.02%. Harmony Biosciences has a consensus price target of $51.6667, indicating a potential upside of 82.44%. Given Oncternal Therapeutics' higher probable upside, analysts clearly believe Oncternal Therapeutics is more favorable than Harmony Biosciences.

Insider and Institutional Ownership

10.8% of Oncternal Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are owned by institutional investors. 10.9% of Oncternal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Oncternal Therapeutics and Harmony Biosciences' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$2.42 million168.49$-34,190,000.00($1.56)-5.29
Harmony BiosciencesN/AN/AN/AN/AN/A

Harmony Biosciences has lower revenue, but higher earnings than Oncternal Therapeutics.

Profitability

This table compares Oncternal Therapeutics and Harmony Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oncternal Therapeutics-746.10%-150.58%-91.87%
Harmony BiosciencesN/AN/AN/A

Oncternal Therapeutics (NASDAQ:ONCT) and Travere Therapeutics (NASDAQ:TVTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Profitability

This table compares Oncternal Therapeutics and Travere Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oncternal Therapeutics-746.10%-150.58%-91.87%
Travere Therapeutics-40.24%-29.27%-12.25%

Analyst Ratings

This is a summary of recent ratings and target prices for Oncternal Therapeutics and Travere Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncternal Therapeutics00503.00
Travere Therapeutics00403.00

Oncternal Therapeutics presently has a consensus price target of $15.20, indicating a potential upside of 84.02%. Travere Therapeutics has a consensus price target of $47.00, indicating a potential upside of 83.52%. Given Oncternal Therapeutics' higher probable upside, analysts clearly believe Oncternal Therapeutics is more favorable than Travere Therapeutics.

Valuation & Earnings

This table compares Oncternal Therapeutics and Travere Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$2.42 million168.49$-34,190,000.00($1.56)-5.29
Travere Therapeutics$175.34 million8.83$-146,430,000.00($3.46)-7.40

Oncternal Therapeutics has higher earnings, but lower revenue than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

10.8% of Oncternal Therapeutics shares are owned by institutional investors. 10.9% of Oncternal Therapeutics shares are owned by insiders. Comparatively, 4.6% of Travere Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Oncternal Therapeutics has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Travere Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Summary

Oncternal Therapeutics beats Travere Therapeutics on 9 of the 13 factors compared between the two stocks.

Oncternal Therapeutics (NASDAQ:ONCT) and Zentalis Pharmaceuticals (NASDAQ:ZNTL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Oncternal Therapeutics and Zentalis Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oncternal Therapeutics-746.10%-150.58%-91.87%
Zentalis PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Oncternal Therapeutics and Zentalis Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncternal Therapeutics00503.00
Zentalis Pharmaceuticals00703.00

Oncternal Therapeutics currently has a consensus price target of $15.20, indicating a potential upside of 84.02%. Zentalis Pharmaceuticals has a consensus price target of $54.2857, indicating a potential upside of 45.11%. Given Oncternal Therapeutics' higher probable upside, equities research analysts clearly believe Oncternal Therapeutics is more favorable than Zentalis Pharmaceuticals.

Earnings and Valuation

This table compares Oncternal Therapeutics and Zentalis Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$2.42 million168.49$-34,190,000.00($1.56)-5.29
Zentalis PharmaceuticalsN/AN/AN/AN/AN/A

Zentalis Pharmaceuticals has lower revenue, but higher earnings than Oncternal Therapeutics.

Insider & Institutional Ownership

10.8% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 67.1% of Zentalis Pharmaceuticals shares are held by institutional investors. 10.9% of Oncternal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Zentalis Pharmaceuticals beats Oncternal Therapeutics on 5 of the 8 factors compared between the two stocks.

Oncternal Therapeutics (NASDAQ:ONCT) and Generation Bio (NASDAQ:GBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Oncternal Therapeutics and Generation Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oncternal Therapeutics-746.10%-150.58%-91.87%
Generation BioN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Oncternal Therapeutics and Generation Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncternal Therapeutics00503.00
Generation Bio00603.00

Oncternal Therapeutics currently has a consensus price target of $15.20, indicating a potential upside of 84.02%. Generation Bio has a consensus price target of $40.60, indicating a potential upside of 49.26%. Given Oncternal Therapeutics' higher probable upside, equities research analysts clearly believe Oncternal Therapeutics is more favorable than Generation Bio.

Earnings and Valuation

This table compares Oncternal Therapeutics and Generation Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$2.42 million168.49$-34,190,000.00($1.56)-5.29
Generation BioN/AN/AN/AN/AN/A

Generation Bio has lower revenue, but higher earnings than Oncternal Therapeutics.

Insider & Institutional Ownership

10.8% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 63.3% of Generation Bio shares are held by institutional investors. 10.9% of Oncternal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Generation Bio beats Oncternal Therapeutics on 5 of the 8 factors compared between the two stocks.

Oncternal Therapeutics (NASDAQ:ONCT) and Kronos Bio (NASDAQ:KRON) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Oncternal Therapeutics and Kronos Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oncternal Therapeutics-746.10%-150.58%-91.87%
Kronos BioN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Oncternal Therapeutics and Kronos Bio, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncternal Therapeutics00503.00
Kronos Bio00403.00

Oncternal Therapeutics currently has a consensus price target of $15.20, indicating a potential upside of 84.02%. Kronos Bio has a consensus price target of $43.6667, indicating a potential upside of 60.07%. Given Oncternal Therapeutics' higher probable upside, equities research analysts clearly believe Oncternal Therapeutics is more favorable than Kronos Bio.

Earnings and Valuation

This table compares Oncternal Therapeutics and Kronos Bio's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$2.42 million168.49$-34,190,000.00($1.56)-5.29
Kronos BioN/AN/AN/AN/AN/A

Kronos Bio has lower revenue, but higher earnings than Oncternal Therapeutics.

Insider & Institutional Ownership

10.8% of Oncternal Therapeutics shares are held by institutional investors. 10.9% of Oncternal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Oncternal Therapeutics beats Kronos Bio on 5 of the 8 factors compared between the two stocks.

Oncternal Therapeutics (NASDAQ:ONCT) and uniQure (NASDAQ:QURE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Oncternal Therapeutics and uniQure's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Oncternal Therapeutics-746.10%-150.58%-91.87%
uniQure-2,738.33%-59.64%-41.47%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Oncternal Therapeutics and uniQure, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Oncternal Therapeutics00503.00
uniQure011113.00

Oncternal Therapeutics currently has a consensus price target of $15.20, indicating a potential upside of 84.02%. uniQure has a consensus price target of $68.4615, indicating a potential upside of 102.91%. Given uniQure's higher probable upside, analysts clearly believe uniQure is more favorable than Oncternal Therapeutics.

Earnings and Valuation

This table compares Oncternal Therapeutics and uniQure's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Oncternal Therapeutics$2.42 million168.49$-34,190,000.00($1.56)-5.29
uniQure$7.28 million208.53$-124,200,000.00($3.11)-10.85

Oncternal Therapeutics has higher earnings, but lower revenue than uniQure. uniQure is trading at a lower price-to-earnings ratio than Oncternal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

10.8% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 78.3% of uniQure shares are held by institutional investors. 10.9% of Oncternal Therapeutics shares are held by insiders. Comparatively, 2.8% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Oncternal Therapeutics has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500. Comparatively, uniQure has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500.

Summary

uniQure beats Oncternal Therapeutics on 8 of the 14 factors compared between the two stocks.


Oncternal Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$28.32-0.2%$1.61 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.2$25.61-1.4%$1.55 billion$175.34 million-15.06
Zentalis Pharmaceuticals logo
ZNTL
Zentalis Pharmaceuticals
1.8$37.41-13.5%$1.54 billionN/A0.00Insider Selling
Generation Bio logo
GBIO
Generation Bio
1.8$27.20-5.3%$1.53 billionN/A0.00Insider Selling
News Coverage
Kronos Bio logo
KRON
Kronos Bio
1.7$27.28-0.3%$1.53 billionN/A0.00Lockup Expiration
Gap Down
uniQure logo
QURE
uniQure
1.7$33.74-5.2%$1.52 billion$7.28 million-8.95
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.60-4.0%$1.52 billion$145.97 million-6.72News Coverage
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.56-3.8%$1.51 billion$82.27 million-18.44Unusual Options Activity
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$28.96-0.4%$1.50 billion$4.23 million-21.45
ATBPD
Antibe Therapeutics
0.1$3.88-0.5%$1.50 billion$7.51 million-6.46Gap Down
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.4$28.31-0.7%$1.50 billion$392.76 million11.75Analyst Revision
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.4$33.30-2.3%$1.49 billionN/A0.00Insider Selling
News Coverage
Cara Therapeutics logo
CARA
Cara Therapeutics
1.6$29.19-5.9%$1.46 billion$19.89 million-13.77High Trading Volume
Unusual Options Activity
News Coverage
Zymeworks logo
ZYME
Zymeworks
1.8$31.00-1.5%$1.43 billion$29.54 million-8.22News Coverage
Endo International logo
ENDP
Endo International
1.3$6.20-1.0%$1.43 billion$2.91 billion-9.12Analyst Report
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.80-1.5%$1.42 billion$6.20 million-14.39Gap Down
Keros Therapeutics logo
KROS
Keros Therapeutics
1.6$60.16-4.3%$1.40 billionN/A0.00
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$20.95-3.9%$1.37 billion$73.41 million-4.43
Arcutis Biotherapeutics logo
ARQT
Arcutis Biotherapeutics
1.6$26.62-3.5%$1.33 billionN/A-2.88
OLMA
Olema Pharmaceuticals
1.6$32.84-0.4%$1.32 billionN/A0.00
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.5$35.80-3.8%$1.31 billionN/A0.00
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$34.35-2.6%$1.26 billionN/A-19.08
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.51-1.3%$1.26 billion$4.23 million-9.22
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
1.9$33.90-7.8%$1.21 billion$57.05 million0.00
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$17.69-2.5%$1.21 billionN/A-7.46
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$38.49-0.2%$1.21 billionN/A-2.75Insider Selling
News Coverage
Innoviva logo
INVA
Innoviva
1.4$11.70-1.6%$1.19 billion$261.02 million5.97
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$19.39-2.9%$1.18 billion$59.70 million-193.90Unusual Options Activity
Shattuck Labs logo
STTK
Shattuck Labs
1.4$28.23-3.0%$1.18 billionN/A0.00Lockup Expiration
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.58-0.5%$1.16 billion$230,000.00-12.36
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.38-8.0%$1.15 billionN/A-8.88High Trading Volume
News Coverage
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$10.07-1.0%$1.14 billion$35.22 million-7.35
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$29.54-1.6%$1.14 billionN/A0.00Unusual Options Activity
Lockup Expiration
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.8$30.78-0.7%$1.14 billionN/A0.00News Coverage
Omeros logo
OMER
Omeros
1.4$18.23-2.9%$1.13 billion$111.81 million-7.66Insider Selling
News Coverage
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.5$15.81-1.8%$1.09 billion$42.12 million-11.71News Coverage
Gap Down
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$22.50-1.4%$1.08 billionN/A-8.30Analyst Report
News Coverage
Zogenix logo
ZGNX
Zogenix
1.7$19.27-0.9%$1.07 billion$3.65 million-2.03Analyst Upgrade
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$10.42-7.3%$1.07 billion$120,000.00-3.86News Coverage
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$25.57-1.3%$1.07 billionN/A-8.82
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$22.16-2.8%$1.07 billion$1.52 million-11.79News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$21.27-1.9%$1.07 billionN/A-7.00
NKTX
Nkarta
1.8$32.28-1.6%$1.06 billionN/A0.00
MannKind logo
MNKD
MannKind
1.4$4.24-1.9%$1.05 billion$63.04 million-20.19News Coverage
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.54-0.1%$992.72 million$800.40 million23.15News Coverage
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.75-1.1%$983.39 million$122.47 million-26.79News Coverage
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$37.00-1.8%$972.36 million$20.79 million-12.76
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.76-1.9%$965.22 millionN/A-12.79
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$28.37-0.2%$958.34 millionN/A-26.27
Annexon logo
ANNX
Annexon
1.9$24.93-0.9%$951.28 millionN/A0.00
This page was last updated on 4/10/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.